Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Shernan Holtan; Todd E. DeFor; Armin Rashidi; Alexander Khoruts; Christopher Staley; Lucie M. Turcotte; Pamala A. Jacobson; Daniel J. Weisdorf; Margaret L. MacMillan

doi:10.1182/blood-2019-129236

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Shernan Holtan, Todd E. DeFor, Armin Rashidi, Alexander Khoruts, Christopher Staley, Lucie M. Turcotte, Pamala A. Jacobson, Daniel J. Weisdorf, Margaret L. MacMillan

Research output: Contribution to journal › Article › peer-review

Abstract

DISCLOSURES: Holtan: Bristol-Myers Squibb: Consultancy; Incyte: Consultancy; Janssen: Consultancy; CSL Behring: Consultancy. Weisdorf:Fate Therapeutics: Consultancy; Pharmacyclics: Consultancy; Incyte: Research Funding. MacMillan:Angiocrine: Membership on an entity's Board of Directors or advisory committees; Equillium: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Alpine Immune Sciences: Consultancy.

Original language	English (US)
Number of pages	1
Journal	Blood
Volume	134
Issue number	1
DOIs	https://doi.org/10.1182/blood-2019-129236
State	Published - Nov 13 2019

PubMed: MeSH publication types

Journal Article

Publisher link

10.1182/blood-2019-129236

Find It

Find It at U of M Libraries

Cite this

@article{5db2d116ea4145fb86bb3d49474397d9,

title = "Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation",

abstract = "DISCLOSURES: Holtan: Bristol-Myers Squibb: Consultancy; Incyte: Consultancy; Janssen: Consultancy; CSL Behring: Consultancy. Weisdorf:Fate Therapeutics: Consultancy; Pharmacyclics: Consultancy; Incyte: Research Funding. MacMillan:Angiocrine: Membership on an entity's Board of Directors or advisory committees; Equillium: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Alpine Immune Sciences: Consultancy.",

author = "Shernan Holtan and DeFor, {Todd E.} and Armin Rashidi and Alexander Khoruts and Christopher Staley and Turcotte, {Lucie M.} and Jacobson, {Pamala A.} and Weisdorf, {Daniel J.} and MacMillan, {Margaret L.}",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/blood-2019-129236",

language = "English (US)",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "1",

}

TY - JOUR

T1 - Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

AU - Holtan, Shernan

AU - DeFor, Todd E.

AU - Rashidi, Armin

AU - Khoruts, Alexander

AU - Staley, Christopher

AU - Turcotte, Lucie M.

AU - Jacobson, Pamala A.

AU - Weisdorf, Daniel J.

AU - MacMillan, Margaret L.

PY - 2019/11/13

Y1 - 2019/11/13

N2 - DISCLOSURES: Holtan: Bristol-Myers Squibb: Consultancy; Incyte: Consultancy; Janssen: Consultancy; CSL Behring: Consultancy. Weisdorf:Fate Therapeutics: Consultancy; Pharmacyclics: Consultancy; Incyte: Research Funding. MacMillan:Angiocrine: Membership on an entity's Board of Directors or advisory committees; Equillium: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Alpine Immune Sciences: Consultancy.

AB - DISCLOSURES: Holtan: Bristol-Myers Squibb: Consultancy; Incyte: Consultancy; Janssen: Consultancy; CSL Behring: Consultancy. Weisdorf:Fate Therapeutics: Consultancy; Pharmacyclics: Consultancy; Incyte: Research Funding. MacMillan:Angiocrine: Membership on an entity's Board of Directors or advisory committees; Equillium: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Alpine Immune Sciences: Consultancy.

UR - http://www.scopus.com/inward/record.url?scp=85074961210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074961210&partnerID=8YFLogxK

U2 - 10.1182/blood-2019-129236

DO - 10.1182/blood-2019-129236

M3 - Article

C2 - 31724001

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

IS - 1

ER -

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Abstract

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this